Skip to main content

Table 1 Role of Plk1 as prognostic marker in clinical tumors

From: Polo-like kinase 1 as target for cancer therapy

Tumor type

Number of tumors

Method

Result

Reference

colorectal cancer

78

immunohistochemistry

expression in tumors higher than in normal tissues

[8]

   

significant correlations with invasion and Duke’s stage

 

advanced rectal cancer

76

immunohistochemistry

significant correlations with tumor regression

[9]

 

20

mRNA microarray

and long-term clinical outcome

 

colorectal carcinoma

56

immunohistochemistry

expression in tumors higher than in normal tissues

[10]

   

significant correlations with Duke’s stage, tumor size,

 
   

invasion, and lymph node metastasis

 

gastric adenocarcinoma

208

immunohistochemistry

expression in tumors higher than in normal tissues

[11]

  

RT-PCR

  

gastric adenocarcinoma

160

immunohistochemistry

prognostic factor for poor survival time

[12]

  

RT-PCR

  

gastric adenocarcinoma

135

immunohistochemistry

expression in tumors higher than in normal tissues

[13]

   

significant correlations with stage, nodal status and diffuse

 
   

growth pattern, no correlation to lymph node metastasis

 

hepatocellular carcinoma

135

immunohistochemistry

expression in tumors higher than in normal tissues,

[14]

 

111

RT-PCR

significant correlations to venous invasion, tumor nodules

 
   

and Edmondson grade, prognostic factor for poor survival time

 

hepatoblastoma

74

RT-PCR

expression in tumors higher than in normal tissues

[15]

non-small cell lung

100

immunohistochemistry

expression in tumors higher than in normal tissues

[16]

cancer

  

significant correlations with stage, grade and lymph

 
   

node metastasis

 

melanoma

36

 

significant correlation with metastasis

 

astrocytic tumors

 

immunohistochemistry

significant correlation with grade of anaplasia

[17]

non-Hodgkin lymphoma

66

immunohistochemistry

prognostic factor for poor survival time

[18]

non-Hodgkin lymphoma

118

immunohistochemistry

significant correlations with grade,

 
   

prognostic factor for poor survival time

 

cutaneous T-cell

49

immunohistochemistry

expression in tumors higher than in patch and

[19]

lymphoma

  

plaque-stage lesions

 

muliple myeloma

188

immunohistochemistry

prognostic factor for poor survival time

[20]

breast carcinoma

135

immunohistochemistry

expression in tumors higher than in normal tissues

[21]

   

no correlation with 10 year survival time

 

breast carcinoma

3093

immunohistochemistry

no correlation with 10 year survival time

[22]

ovarian tumors

17

immunohistochemistry

significant correlation with grade

[23]

ovarian tumors

107

immunohistochemistry

expression in high malignant tumors than in low

[24]

   

malignant tumors, prognostic factor for poor survival time

 

endometrial tumors

20

immunohistochemistry

significant correlation with grade

[25]

cervical carcinoma

36

immunohistochemistry

significant correlation with tumor size

[26]